U.S. Pharmacogenomics (PGx) Testing Market Size By Test Type(single gene tests, array-based tests, whole genome sequencing), By Sample Type(blood, saliva), By Application(oncology, neurology, cardiology, genomics), By End–User(hospitals, clinics, diagnostic laboratories), By Distribution Channel(hospital pharmacies, retail pharmacies) And Forecast

U.S. Pharmacogenomics (PGx) Testing Market Size And Forecast

U.S. Pharmacogenomics (PGx) Testing Market size was valued at USD 376.34 Million in 2021 and is projected to reach USD 794.91 Million by 2030, growing at a CAGR of 9.32% from 2023 to 2030.

The pharmacogenomic (PGx) testing market is predicted to rise as a result of the expanding patient-specific approach to the treatment of chronic diseases and research into factors that can affect therapy, such as genetic characteristics that may affect the desired effect of medication.  The U.S. Pharmacogenomics (PGx) Testing Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

U.S. Pharmacogenomics (PGx) Testing Market Definition

A pharmacogenetic test, also termed a drug-gene test, is used to research, and establish how well a drug interacts with a person’s genetic makeup. According to the expression of the genes the drug induces, different people respond to drugs in different ways. The impact of the medication is significantly influenced by the patient’s age, lifestyle, surroundings, and other medications they are taking. These elements are taken into account in the pharmacogenetic tests to give the patient the proper drug and treatment alternatives.

Moreover, pharmacogenetic tests help the doctor decide which medication is best for the patient undergoing the test. Pharmacogenetic research looks for gene variations that might affect how medicine works and might assist evaluate what kind of an impact a drug has on a particular person. Pharmacogenetic tests require blood or mouth swabs as the sample material and are simple and reliable. The specificity and sensitivity detection of this evidence-based medication management are becoming more well-known. Recent developments in the pharmacogenetic test market allow for simple result access on a smart device owing to direct-to-customer services.

U.S. Pharmacogenomics (PGx) Testing Market Overview

Pharmacogenomics (PGx) is the study of how a person’s genetic composition influences how they respond to medication therapy. The discipline of precision medicine, which attempts to treat each patient uniquely, includes pharmacogenomics. Analyzing individual drug responses using genomic data, assists healthcare professionals in selecting the best medication for every patient. The traditional one-size-fits-all approach to dosage and drug selection can be replaced by medication that is specifically formulated for each patient based on their genetic traits.

Moreover, Pharmacogenomic (PGx) testing examines how well a person’s genetic makeup affects the therapeutic effects of a drug. Age, weight, genetics, habits, diet, and other variables all affect how much each person reacts to the drug. The rate at which a drug is metabolized depends largely on an individual’s genetic makeup, among other factors. The metabolism of the medication varies greatly depending on the genetic differences between individuals. Due to differences in the rate of metabolism, a medicine that is effective for one individual may not be effective for another.The U.S. pharmacogenetic (PGx) testing market may experience an increase in the upcoming year as a result of technological advancements in molecular diagnostics procedures for a better understanding of the genetic makeup of specific patients. Additionally, the market for

pharmacogenomic (PGx) testing is anticipated to rise as more patients are treated individually. The market for pharmacogenomic (PGx) testing is predicted to develop as a result of the rising emphasis placed by healthcare professionals on minimizing severe adverse drug reactions which differ greatly from person to person. The pharmacogenomic (PGx) testing market is predicted to rise as a result of the expanding patient-specific approach to the treatment of chronic diseases and research into factors that can affect therapy, such as genetic characteristics that may affect the desired effect of medication.

U.S. Pharmacogenomics (PGx) Testing MarketSegmentation Analysis

The U.S. Pharmacogenomics (PGx) Testing Market is segmented into the test type, sample type, application,end–user, and distribution channel.

U.S. Pharmacogenomics (PGx) Testing Market by Test Type

• Single Gene Tests
• Array-based Tests
• Whole Genome Sequencing
• NGS and whole exome sequencing

To Get Summarized Market Report By Test Type -

On the basis of test type, the market is divided into single gene tests, array-based tests, whole genome sequencing, NGS and whole exome sequencing. In 2021, the array-based tests segment accounted largest market share of the U.S. Pharmacogenomics (PGx) Testing market.

U.S. Pharmacogenomics (PGx) Testing Market by Sample Type

• Blood
• Saliva
• Others

To Get Summarized Market Report By Sample Type -

Based on the sample type segment, the market is split into blood, saliva, and others. In 2021, the blood segment accounted largest market share of the U.S. Pharmacogenomics (PGx) Testing market.

U.S. Pharmacogenomics (PGx) Testing Market by Application

• Oncology
• Neurology
• Cardiology
• Genomics
• Immunology and hypersensitivity
• Pain management
• Others

To Get Summarized Market Report By Application-

Based on Application, the market is segmented into oncology, neurology, cardiology, genomics, immunology and hypersensitivity, pain management, and others. In 2021, the oncology category accounted for a significant portion of the U.S. pharmacogenomics (PGx) testing market.

U.S. Pharmacogenomics (PGx) Testing Market by End-User

• Hospitals
• Clinics
• Diagnostic laboratories
• Others

To Get Summarized Market Report By End-User -

Based on End-User, the market is segmented into hospitals, clinics, diagnostic laboratories, and others. In 2021, the hospital segment accounted for a significant portion of the U.S. pharmacogenomics (PGx) testing market.

U.S. Pharmacogenomics (PGx) Testing Market by Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online
• Others

Based on distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, online, and others. In 2021, the hospital pharmacies segment accounted for a significant portion of the U.S. pharmacogenomics (PGx) testing market.

Key Players

The major players in the market are 23andMe Inc, Bayer, BGI, Eurofins USA, Genelex, GENEWIZ, Illumina Inc., Luminex Corporation, Thermo Fisher Scientific Inc., Mako Medical Laboratories LLC, Myriad Genetics Inc., OneOme LLC, Pacific Biosciences of California, Inc., PerkinElmer Inc., PGXT, QIAGEN, Rxight, and Sonic Healthcare amongst other major companies operating in the U.S. pharmacogenomics (PGx) testing Market.

The competitive landscape section also includes a United States study of the above-mentioned competitors’ primary development strategies, market share, and market ranking.

Key Developments

• In Novemmber 2022, Bayer announced the acquisition of German biotechnology start-up Targenomix. A spin-off from the Max Planck Institute for Molecular Plant Physiology (MPI MPP), it uses novel systems biology and computational life science tools to identify new modes of action of crop protection compounds.

• In February 2021, Virgin Group’s VG Acquisition Corp. and 23andMe will merge to become a publicly traded company that will revolutionize personalized healthcare and therapeutic development using human genetics.

• In January 2021, Azenta Life Sciences announced that GENEWIZ, a genomics analytics company, has been awarded one of six Indefinite Delivery Indefinite Quantity (IDIQ) Genome Characterization Center contracts from the National Cancer Institute (NCI).

• In March 2020, Invitae Corporation announced that it has entered into definitive agreements to acquire YouScript, a privately held clinical decision support and analytics platform, and Genelex, a privately held pharmacogenetic testing company, which will bring best-in-class pharmacogenetic testing and robust, integrated clinical decision support.

Report Scope

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly 

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which inco